{
  "id": 11164355,
  "title": "The Next Generation of Weight-Loss Drugs Is Almost Here",
  "url": "https://urgent.news/2026/10/01/the-next-generation-of-weight-loss-drugs-is-almost-here",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-01T10:00:04.000Z",
  "source": {
    "name": "Time",
    "slug": "time",
    "url": "https://time.com/article/2026/10/01/next-generation-of-weight-loss-drugs-is-almost-here/"
  },
  "original_language": "en",
  "account": "Weight-loss drugs that mimic GLP-1, a hormone in the gut, have been gaining traction for treating obesity and diabetes. However, their side effects, primarily affecting the gastrointestinal system, cause around 40% of users to discontinue use within a year. At the European Association for the Study of Diabetes meeting in Milan, researchers from companies behind popular weight-loss medications unveiled promising results from a new class of injectable drugs, amylins. Amylins, which work similarly to GLP-1s by suppressing appetite and controlling stomach emptying, may offer fewer side effects. Novo's study revealed that their experimental amylin-based drug, CagriSema, taken as a weekly injection, helped overweight or obese individuals lose 22.4% of their starting body weight after a year compared to those on a placebo. Additionally, CagriSema altered brain responses to food, potentially reducing cravings. The drug also lowered harmful fat in the liver and pancreas in people with Type 2 diabetes. Novo's chief scientific officer, Martin Holst Lange, expressed excitement about the drug's potential to improve patients' overall well-being. Eli Lilly reported that EloraTZP, a combination of its amylin analogue and the GLP-1 drug tirzepatide, led to a 23% weight loss in people with obesity and Type 2 diabetes, compared to 14.8% with tirzepatide alone. Zealand Pharmaceuticals shared results from its study of another amylins-based compound, petrelintide, showing an average 10% weight loss in overweight individuals without diabetes. Amylin-based medications' attractive side-effect profile may make them ideal first-line treatments for people seeking moderate weight loss without the unpleasant side effects of GLP-1 drugs.",
  "summary": "Scientists are exploring a new group of hormones—beyond GLP-1s—to target for weight loss.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}